High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

by Martin J Boeree, Norbert Heinrich, Rob Aarnoutse et al.
Lancet Infect Dis 2016, Published Online: October 26, 2016

11 pp. 301 kB
http://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(16)30274-2.pdfcov200h

Tuberculosis is the world’s leading infectious disease killer. The authors aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. They conclude that a dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens. Their adaptive trial design was successfully implemented in a multi-centre, high tuberculosis burden setting, and could speed regimen development at reduced cost.

(Visited 41 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.